Our therapy is based on the encapsulation and implantation of pancreatic
beta cell progenitors (Pro-Islet-1) derived from human stem cells which secrete insulin in patients.
The Company's technology is based on pancreatic
beta cell progenitors derived from human pluripotent stem cells.
Our therapy is based on pancreatic
beta cell progenitors (Pro-Islet (TM)-RRB- derived from human pluripotent stem cells.
Not exact matches
«By identifying the signals that instruct mouse
progenitor cells to become
cells that make tubes and later insulin - producing
beta cells, we can transfer this knowledge to human stem
cells to more robustly make
beta cells, says Professor and Head of Department Henrik Semb from the Novo Nordisk Foundation Center for Stem
Cell Biology at the Faculty of Health and Medical Sciences.
It is a really amazing and simple mechanism, and by affecting the
progenitor cells» so - called polarity we can control their conversion into
beta cells», says Pia Nyeng.
But the extracted tissue began producing insulin, glucagon and other hormones after the newly identified
cells were added, indicating that they were indeed
progenitors capable of differentiating into all the islet
cell types, including
beta cells.
In addition, when these inhibitory
progenitor cells were transplanted into apoE4 mice with an accumulation of amyloid
beta, prior deficits were alleviated.
In the study, which was conducted in collaboration with researchers at UC San Francisco and published today in the Journal of Neuroscience, scientists transplanted inhibitory neuron
progenitors — early - stage brain
cells that have the capacity to develop into mature inhibitory neurons — into two mouse models of Alzheimer's disease, apoE4 or apoE4 with accumulation of amyloid
beta, another major contributor to Alzheimer's.
The
beta - catenin / TCF4 complex imposes a crypt
progenitor phenotype on colorectal cancer
cells.
The PEC - EnCap (formerly VC - 01 ™) product candidate delivers pancreatic
progenitor cells in the Encaptra ® immunoprotective device, and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin - producing
beta cell function.
The PEC - EnCap (formerly VC - 01 ™) product candidate delivers pancreatic
progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin - producing
beta cell function.